Garlic chemical tablet treats diabetes I and II
When Hiromu Sakurai and colleagues from the Suzuka University of Medical Science, Japan, gave the drug orally to type I diabetic mice, they found it reduced blood glucose levels.
The drug is based on vanadium and allixin, a compound found in garlic, and its action described in an Advance Article from Metallomics available free online from today. The first issue of the new journal will be published in 2009.
In previous work they had discovered the vanadium-allixin compound treated both diabetes types when injected, but this new study shows the drug has promise as an oral treatment for the disease.
Type I diabetes (insulin dependent) is currently treated with daily injections of insulin, while type II (non-insulin dependent) is treated with drugs bearing undesirable side-effects – the authors note neither treatment is ideal.
The researchers aim to test the drug in humans in future work.
Media Contact
All latest news from the category: Health and Medicine
This subject area encompasses research and studies in the field of human medicine.
Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
